Evidence map›Paper›PMID 24326276›Full record

ArticleBioorganic & medicinal chemistry2014

Comparative molecular field analysis of fenoterol derivatives interacting with an agonist-stabilized form of the β₂-adrenergic receptor.

Anita Plazinska, Karolina Pajak, Ewelina Rutkowska, Lucita Jimenez, Joseph Kozocas, Gary Koolpe, Mary Tanga, Lawrence Toll, Irving W Wainer, Krzysztof Jozwiak

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Novel fenoterol derivatives as suppressors of ERK1/2 phosphorylation in melanoma.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Discovery of β-arrestin-biased βActa pharmacologica Sinica · 2019
    Article
  6. Recruitment of β-arrestin 1 and 2 to the β2-adrenoceptor: analysis of 65 ligands.The Journal of pharmacology and experimental therapeutics · 2015
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Anita PlazinskaMedical University of Lublin, Lublin, Poland.
Karolina PajakMedical University of Lublin, Lublin, Poland.
Ewelina RutkowskaMedical University of Lublin, Lublin, Poland.
Lucita JimenezSRI International, Menlo Park, CA, United States.
Joseph KozocasSRI International, Menlo Park, CA, United States.
Gary KoolpeSRI International, Menlo Park, CA, United States.
Mary TangaSRI International, Menlo Park, CA, United States.
Lawrence TollTorrey Pines Institute for Molecular Studies, Port St. Lucie, FL, United States.
Irving W WainerLaboratory of Clinical Investigation, National Institute on Aging Intramural Research Program, Baltimore, MD, United States.
Krzysztof JozwiakMedical University of Lublin, Lublin, Poland. Electronic address: krzysztof.jozwiak@umlub.pl.
Medical University of Lublin · PLMenlo School · USNational Institute on Aging · USSRI International · USTorrey Pines Institute For Molecular Studies · US

Funding

Disease Status Drug Metabolism and New Drug Discovery ZIAAG000297 · NIA · NATIONAL INSTITUTE ON AGING · PI EGAN, JOSEPHINE · 2009 to 2025
$38.2M
Intramural NIH HHS ZIA AG000297NIA NIH HHS N01 AG031009
6 · The paper itself

Abstract

The β₂-adrenergic receptor (β₂-AR) agonist [(3)H]-(R,R')-methoxyfenoterol was employed as the marker ligand in displacement studies measuring the binding affinities (Ki values) of the stereoisomers of a series of 4'-methoxyfenoterol analogs in which the length of the alkyl substituent at α' position was varied from 0 to 3 carbon atoms. The binding affinities of the compounds were additionally determined using the inverse agonist [(3)H]-CGP-12177 as the marker ligand and the ability of the compounds to stimulate cAMP accumulation, measured as EC₅₀ values, were determined in HEK293 cells expressing the β₂-AR. The data indicate that the highest binding affinities and functional activities were produced by methyl and ethyl substituents at the α' position. The results also indicate that the Ki values obtained using [(3)H]-(R,R')-methoxyfenoterol as the marker ligand modeled the EC₅₀ values obtained from cAMP stimulation better than the data obtained using [(3)H]-CGP-12177 as the marker ligand. The data from this study was combined with data from previous studies and processed using the Comparative Molecular Field Analysis approach to produce a CoMFA model reflecting the binding to the β₂-AR conformation probed by [(3)H]-(R,R')-4'-methoxyfenoterol. The CoMFA model of the agonist-stabilized β₂-AR suggests that the binding of the fenoterol analogs to an agonist-stabilized conformation of the β₂-AR is governed to a greater extend by steric effects than binding to the [(3)H]-CGP-12177-stabilized conformation(s) in which electrostatic interactions play a more predominate role.

Indexed as

FenoterolHumansLigandsModels, MolecularReceptors, Adrenergic, beta-2StereoisomerismFenoterolLigandsmethoxyfenoterolReceptors, Adrenergic, beta-2[(3)H]-(R,R′)-4′-methoxyfenoterolAgonist-stabilized conformationsAntagonist-stabilized conformationsβ(2)-Adrenoceptor conformationsβ(2)-Adrenoceptor selective agonist

Identifiers

PMID24326276
PMCPMC3908673
OpenAlexW1984126432

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.